Kazia Therapeutics Limited Stock News

U.S. stocks traded slightly lower this morning, after recording gains in the previous session. Following the market opening Monday, the Dow traded down 0.28% to 32,752.14 while the NASDAQ fell 0.04% t

Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.

Kazia Therapeutics (KZIA) stock is taking off on Wednesday following an update from the FDA on its pediatric cancer treatment. The post Kazia Therapeutics (KZIA) Stock Soars on FDA Designation appeare

SYDNEY , May 23, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be pres

SYDNEY , April 29, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of p

Kazia Therapeutics says it had $15.2 million in cash at the end of December 2021 having committed $11.4 million during the period to progress its

Kazia Therapeutics Limited (ASX:KZA) insider Steven Coffey purchased 50,000 shares of the stock in a transaction on Monday, December 20th. The shares were purchased at an average price of A$1.08 ($0.77) per share, with a total value of A$54,150.00 ($38,404.26). About Kazia Therapeutics Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead []

Kazia Therapeutics Limited (NASDAQ:KZIA) was the target of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 6,300 shares, an increase of 162.5% from the November 15th total of 2,400 shares. Based on an average daily trading volume, of 30,200 shares, the short-interest ratio []

Los Angeles, USA, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Glioblastoma Pipeline Analysis | Clinical Trials Report 2021 | DelveInsight There are approximately 150+ key companies developing Glioblastoma therapies. The companies with Glioblastoma drug candidates in the most advanced stage are Kintara Therapeutics, Diffusion Pharmaceuticals, Celgene Corporation, Bio-Thera Solutions. DelveInsight''s " Glioblastoma Pipeline Insight " report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Glioblastoma pipeline landscapes. It comprises Glioblastoma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Glioblastoma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Glioblastoma pipeline products. Some of the key takeaways from the Glioblastoma Pipeline Report Major companies such as Celgene Corporation, Myeloid Therapeutics, Genenta Science, Inovio Pharmaceuticals, Apogenix, Oncoceutics, Laminar Pharmaceuticals, Celgene Corporation, Bristol-Myers Squibb, Kintara Therapeutics, Kazia Therapeutics, Oncotelic Therapeutics, AstraZeneca, Genentech, Accendatech, Pfizer, Curtana Pharmaceuticals, Crimson BioPharm, Hope Biosciences, and others are developing potential drug candidates to improve the Glioblastoma treatment scenario.

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones surged more than 200 points in the previous session. Investors are awaiting earnings results from Qudian

Kazia Therapeutics Ltd (NASDAQ: KZIA) announced it has appointed Karen Krumeich as Chief Financial Officer. These are the details.

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed Karen Krumeich as chief financial officer to focus on building and maintaining relationships with US investors, preparing the company for f

Maxim Group reissued their buy rating on shares of Kazia Therapeutics (NASDAQ:KZIA) in a research note published on Friday, Price Targets.com reports. Maxim Group currently has a $18.00 price target on the stock. Shares of NASDAQ KZIA opened at $7.92 on Friday. The business has a 50-day moving average of $10.83 and a 200-day moving [] The post Maxim Group Reiterates Buy Rating for Kazia Therapeutics (NASDAQ:KZIA) appeared first on ETF Daily News .

Maxim Group restated their buy rating on shares of Kazia Therapeutics (NASDAQ:KZIA) in a research report sent to investors on Friday, AnalystRatings.com reports. They currently have a $18.00 price target on the stock. KZIA opened at $9.15 on Friday. Kazia Therapeutics has a 52-week low of $8.48 and a 52-week high of $14.89. The businesss []